Oral Wegovy Surge and Guidance Raise Bolster Novo Nordisk's Fundamentals, But Cautious Monitoring of Durability Remains

What happened

Novo Nordisk's oral Wegovy has surpassed 3 million U.S. prescriptions in just over five months, with 80% of patients new to GLP-1 therapy, expanding the obesity market significantly. Management responded by raising 2026 guidance, citing stronger-than-expected GLP-1 sales and international growth. However, the DeepValue report highlights that this surge must be viewed alongside a one-time $4.2 billion 340B revenue recognition that inflates 1Q26 reported numbers and ongoing GLP-1 volume share losses in 2025. The key test will be whether demand persists after self-pay promotional offers step down on August 31, 2026, and whether EU approval converts into successful launches in 2H26. While the stock at 12.1x P/E offers a margin of safety if fundamentals stabilize, investors should not extrapolate the early prescription velocity without evidence of repeat fills and payer coverage sustainability.

Implication

The strength of oral Wegovy's launch validates the product's market-expanding potential and supports the base case of durable demand. However, full conviction requires confirmation through the Aug-Dec 2026 self-pay step-down and tangible EU launches. If these catalysts materialize, the current 12x P/E offers mid-teens annualized returns without multiple expansion. Position sizing should reflect the binary nature of the next six months.

Thesis delta

The news accelerates the bull case by providing real-world evidence of oral Wegovy's ability to attract new patients and drive topline growth, but it does not resolve the central uncertainty around pricing durability and competitive share stabilization. The thesis shifts from 'potential' to 'conditional confirmation'—the stock now prices in a higher probability of success, narrowing the margin of safety. The key watchpoint is whether the guidance raise was partly aided by the 340B accounting boost, which will normalize in subsequent quarters.